Bluejay Diagnostics Completes $4.5 Million At-The-Market Private Placement in Accordance with Nasdaq Regulations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 10 2025
0mins
Source: Yahoo Finance
Private Placement Announcement: Bluejay Diagnostics, Inc. has completed a private placement of 2,250,000 shares of common stock and Series F warrants, raising $4.5 million to fund FDA approval processes and research activities.
Product Development Focus: The company is developing the Symphony System for rapid sepsis testing, with its first product candidate, an IL-6 Test, aimed at providing quick and reliable results to improve patient triage and treatment decisions.
Analyst Views on BJDX
About BJDX
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
